new_0222_0359|PRLD|0|total_current_assets|cash_on_hand|inventories_net|net_ppe|goodwill_and_intangible|liabilities|total_current_liabilities|total_long_term_liab|total_deposits|book_value_of_equity|retained_earnings|treasury_stock|ev_revenues|ev_earnings|ev_free_cash_flow|ev_assets|ps_ratio|pe_ratio|price_to_book_value|peg_ratio|debt_equity_ratio|dividend_yield|shareholder_yield_ttm|percent_of_shares_outstanding|receivables|payables|capital_stock|return_on_invested_capital|quality_ratio_fractile|momentum_fractile|market_beta_12_month|sustainable_growth_rate|institutional_investor_ownership_percentage|average_shares_outs_diluted|total_employee_number|eps|sga_expense|shares_outstanding|repurchase_of_capital_stock|ordinary_shares_number|payout_ratio|quick_ratio|normalized_eps|stock_buyback|effective_tax_rate|return_on_equity|net_income_ttm|revenues_ttm|dividend_per_share|revenues|gross_profit|pre_tax_income|net_income|interest_income|price|total_return_price|enterprise_value|average_volume_30|one_year_return|short_interest|forward_pe_ratio|forward_pe_ratio_1y|forward_ps_ratio|forward_ps_ratio_1y|quarterly_eps_estimates|quarterly_sales_estimates|quarterly_eps_surprise|quarterly_sales_surprise|quarterly_eps_actual|quarterly_sales_actual|sales_est_0y|sales_est_1y|price_target|consensus_recommendation|price_target_num_est|eps_est_0y|eps_est_1y|r_and_d_expense|reconciled_depreciation|interest_expense_non_operating|land_and_improvements|buildings_and_improvements|other_properties|machinery_furniture_equipment|price_next_month|price_second_month
new_0222_0359|PRLD|1|Prelude Therapeutics Inc Total Current Assets (Quarterly) (USD)|Prelude Therapeutics Inc Cash and Short Term Investments (Quarterly) (USD)|Prelude Therapeutics Inc Inventories (Quarterly) (USD)|Prelude Therapeutics Inc Net PP&E (Quarterly) (USD)|Prelude Therapeutics Inc Goodwill and Intangibles (Quarterly) (USD)|Prelude Therapeutics Inc Total Liabilities (Quarterly) (USD)|Prelude Therapeutics Inc Total Current Liabilities (Quarterly) (USD)|Prelude Therapeutics Inc Total Long Term Liabilities (Quarterly) (USD)|Prelude Therapeutics Inc Total Deposits (Quarterly) (USD)|Prelude Therapeutics Inc Book Value (Quarterly) (USD)|Prelude Therapeutics Inc Retained Earnings (Quarterly) (USD)|Prelude Therapeutics Inc Treasury Stock (Quarterly) (USD)|Prelude Therapeutics Inc EV to Revenues|Prelude Therapeutics Inc EV to Earnings|Prelude Therapeutics Inc EV to Free Cash Flow|Prelude Therapeutics Inc EV to Assets (Quarterly)|Prelude Therapeutics Inc PS Ratio|Prelude Therapeutics Inc PE Ratio|Prelude Therapeutics Inc Price to Book Value|Prelude Therapeutics Inc PEG Ratio|Prelude Therapeutics Inc Debt to Equity Ratio|Prelude Therapeutics Inc Dividend Yield|Prelude Therapeutics Inc Shareholder Yield (TTM)|Prelude Therapeutics Inc Percent of Shares Outstanding Short|Prelude Therapeutics Inc Total Receivables (Quarterly) (USD)|Prelude Therapeutics Inc Total Payables (Quarterly) (USD)|Prelude Therapeutics Inc Total Capital Stock (Quarterly) (USD)|Prelude Therapeutics Inc Return on Invested Capital|Prelude Therapeutics Inc Quality Ratio Score|Prelude Therapeutics Inc Momentum Score|Prelude Therapeutics Inc Beta (1Y)|Prelude Therapeutics Inc Sustainable Growth Rate (TTM)|Prelude Therapeutics Inc Institutional Investor Ownership Percentage|Prelude Therapeutics Inc Average Diluted Shares Outstanding (Quarterly)|Prelude Therapeutics Inc Total Employees (Annual)|Prelude Therapeutics Inc EPS Diluted (Quarterly) (USD)|Prelude Therapeutics Inc SG&A Expense (Quarterly) (USD)|Prelude Therapeutics Inc Shares Outstanding|Prelude Therapeutics Inc Repurchase of Capital Stock (Quarterly) (USD)|Prelude Therapeutics Inc Ordinary Shares Number (Quarterly)|Prelude Therapeutics Inc Payout Ratio|Prelude Therapeutics Inc Quick Ratio (Quarterly)|Prelude Therapeutics Inc Normalized Diluted EPS (Quarterly) (USD)|Prelude Therapeutics Inc Stock Buybacks (Quarterly) (USD)|Prelude Therapeutics Inc Effective Tax Rate (TTM)|Prelude Therapeutics Inc Return on Equity|Prelude Therapeutics Inc Net Income (TTM) (USD)|Prelude Therapeutics Inc Revenue (TTM) (USD)|Prelude Therapeutics Inc Dividend Per Share (Quarterly) (USD)|Prelude Therapeutics Inc Revenue (Quarterly) (USD)|Prelude Therapeutics Inc Gross Profit (Quarterly) (USD)|Prelude Therapeutics Inc Pre-Tax Income (Quarterly) (USD)|Prelude Therapeutics Inc Net Income (Quarterly) (USD)|Prelude Therapeutics Inc Net Interest Income (Quarterly) (USD)|Prelude Therapeutics Inc Price (USD)|Prelude Therapeutics Inc Total Return Price (USD)|Prelude Therapeutics Inc Enterprise Value (USD)|Prelude Therapeutics Inc 30-Day Average Daily Volume|Prelude Therapeutics Inc 1 Year Price Returns (Daily)|Prelude Therapeutics Inc Short Interest|Prelude Therapeutics Inc PE Ratio (Forward)|Prelude Therapeutics Inc PE Ratio (Forward 1y)|Prelude Therapeutics Inc PS Ratio (Forward)|Prelude Therapeutics Inc PS Ratio (Forward 1y)|Prelude Therapeutics Inc Quarterly EPS Estimates (USD)|Prelude Therapeutics Inc Quarterly Revenue Estimates (USD)|Prelude Therapeutics Inc Quarterly EPS Surprise|Prelude Therapeutics Inc Quarterly Revenue Surprise|Prelude Therapeutics Inc Quarterly Actual EPS (USD)|Prelude Therapeutics Inc Quarterly Actual Revenue (USD)|Prelude Therapeutics Inc Revenue Estimates for Current Fiscal Year (USD)|Prelude Therapeutics Inc Revenue Estimates for Next Fiscal Year (USD)|Prelude Therapeutics Inc Price Target (USD)|Prelude Therapeutics Inc Consensus Recommendation|Prelude Therapeutics Inc Price Target Num Estimates|Prelude Therapeutics Inc EPS Estimates for Current Fiscal Year (USD)|Prelude Therapeutics Inc EPS Estimates for Next Fiscal Year (USD)|Prelude Therapeutics Inc Research and Development Expense (Quarterly) (USD)|Prelude Therapeutics Inc Reconciled Depreciation (Quarterly) (USD)|Prelude Therapeutics Inc Non-Operating Interest Expense (Quarterly) (USD)|Prelude Therapeutics Inc Land and Improvements (Quarterly) (USD)|Prelude Therapeutics Inc Buildings and Improvements (Quarterly) (USD)|Prelude Therapeutics Inc Other Properties (Quarterly) (USD)|Prelude Therapeutics Inc Machine, Furniture & Equipment (Quarterly) (USD)||
new_0222_0359|PRLD|2|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|percent_USD_metric|percent_USD_metric|percent_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|percent_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_beta|percent_USD_metric|percent_USD_metric|mil_figure_USD_metric|figure_whole_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_USD_metric|mil_figure_money_USD_metric|mil_figure_USD_metric|percent_USD_metric|figure_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|percent_USD_metric|percent_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_price|figure_money_USD_price|mil_figure_money_USD_metric|figure_USD_metric|percent_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|percent_USD_per_share_metric|percent_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_price|figure_USD_metric|figure_whole_USD_price|figure_money_USD_per_share_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric||
new_0222_0359|PRLD|4|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|quarterly|quarterly|quarterly|daily|quarterly|quarterly|daily|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|daily|daily|daily|daily|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|monthly|monthly|monthly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly||
new_0222_0359|PRLD|5|106.5|106.5||106.5||106.5|106.5|106.5||106.5|106.5||||1.44755244755||||1.44571428571|||1.44759206799||15.25||106.5|106.5|||30.6666666667|30.75|||91.375|91.4|91.375|91.375|25.5625||106.5|||91.375|91.3333333333|||91.4|||||91.375|91.375||1.44759206799|1.44759206799|1.44759206799|1.45061728395|1.42574257426|15.25|||||91.3333333333|91.4285714286|91.25||91.25|91.5|50.75|101.5|18.72|16.1379310345|18.72|18|22.2857142857|91.375|91.375||||106.5|122||
new_0222_0359|PRLD|6|6|6||6||6|6|6||6|6||||286||||350|||353||32||6|6|||3|4|||8|5|8|8|16||6|||8|6|||5|||||8|8||353|353|353|324|101|32|||||9|7|4||4|2|4|2|25|29|25|26|21|8|8||||6|3||
new_0222_0359|PRLD|7|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|quarterly|daily|quarterly|daily|daily|daily|daily|quarterly|daily|quarterly|daily|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|monthly|quarterly|monthly|quarterly|yearly|quarterly|quarterly|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|market_daily|market_daily|daily|market_daily|market_daily|daily|daily|daily|daily|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|daily|daily|daily|daily|daily|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly||
new_0222_0359|PRLD|201909||||||||||||||||||||||||||||||||||32.4018||-0.2078|1.394||||||-0.2078|||||||||-6.734|-6.734|||||||||||||||||||||||||5.49|0.099|||||||
new_0222_0359|PRLD|201912|20.224|18.879||1.647||71.283|4.835|66.448||-49.412|-50.497|||||||||||||||1.974||||||||32.4018||-0.3098|1.246|||42.4546|||-0.3098|||||||||-10.039|-10.039|||||||||||||||||||||||||8.849|0.128||||1.842|0.049||
new_0222_0359|PRLD|202003||||||||||||||||||||||||||||||||||32.4018||-0.2935|1.201||||||-0.2935|||||||||-9.511|-9.511|||||||||||||||||||||||||8.536|0.132|||||||
new_0222_0359|PRLD|202006|30.697|29.716||1.575||102.058|5.639|96.419||-69.311|-71.416|||||||||||||||3.471||||||||42.4546|51|-0.2687|1.66|||42.4546|||-0.2687||||-37.692|||||-11.408|-11.408|||||||||||||||||||||||||9.776|0.135|||||||
new_0222_0359|PRLD|202009|238.061|234.792||1.62||11.374|11.359|0.015||228.307|-88.176||||||||5.7676|||||0.0132||5.074|0.004||||||85.9318|3.1945|55|-5.25|2.851|43.7034||43.7034|||-5.25|-167.929|||-47.718|||||-16.76|-16.76||30.13|30.13|1081.9914|117394.5333||5757|||||-0.345||-11.1565||-0.3835||||35.5|3|2|-1.77|-1.8767|15.293|0.142||||||35.23|51.47
new_0222_0359|PRLD|202012|220.809|218.309||2.48||11.407|11.375|0.032||212.183|-107.426||||-62.1572||||14.738|||||2.8086||3.92|0.004|||||||43.7057|68|-0.4404|4.874|43.7057||43.7057|||-0.4404|1.299|||-56.929|||||-19.25|-19.25||71.55|71.55|2908.8338|195008.9667||1227525|||||-0.4933||10.719||-0.4405||||48|3|3|-3.4933|-2.0767|14.572|0.133||||3.01|0.105|64.95|62.33
new_0222_0359|PRLD|202103|365.018|362.99||4.813||13.264|12.424|0.84||356.567|-128.726||||-30.8656||||5.686|||||3.6742||4.842|0.005|||||||45.122|105|-0.47|5.497|46.7909||46.7909|||-0.47|-161.424|||-68.718|||||-21.3|-21.3||43.33|43.33|1664.4597|200349.4333||1719180|||||-0.424||-10.8491||-0.47||||62.5|2.75|4|-1.87|-2.805|16.47|0.16||||4.813||41.44|34.76
new_0222_0359|PRLD|202106|344.575|343.119||5.006||15.22|14.677|0.543||334.361|-155.591||||-15.3749||||4.0277|||||7.231||6.844|0.005|||||||46.0571|100|-0.58|5.513|47.0387||47.0387|||-0.58||||-84.175|||||-26.865|-26.865||28.63|28.63|1003.599|224939.7||3401355|||||-0.494||-17.4089||-0.58||||62|2.2|5|-2.346|-3.282|22.409|0.199||||5.006||32.04|35.69
new_0222_0359|PRLD|202109|325.897|320.865||5.32||19.975|19.663|0.312||311.242|-186.278||||-15.3787||||4.7383|||||9.4094||11.062|0.005|||4|2.5212|||46.3308|113|-0.66|8.115|47.1918||47.1918|||-0.66||||-98.102|||||-30.687|-30.687||31.25|31.25|1153.8788|354084.1|3.7172|4440453|||||-0.625||-5.6||-0.66||||47.5|1.75|4|-2.345|-3.295|22.721|0.266||||5.32||17.58|14.29
new_0222_0359|PRLD|202112|||||||||||||||-3.5581||||1.8887|||||10.8962||||||1|-1.1063||||||||||||||||||||||||12.45|12.45|266.9667|468497.9333|-82.5996|5144659|||||-0.6825||||||||41.75|1.75|4|-2.4025|-3.365||||||||9.93|10.03
new_0222_0359|PRLD|202203|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||-0.69|||||||||||||||||||||
new_0222_0359|PRLD|202206|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||-0.735|||||||||||||||||||||
new_0222_0359|PRLD|202209|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||-0.77|||||||||||||||||||||
new_0222_0359|PRLD|202212|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||-0.81|||||||||||||||||||||